The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FOCIS 2015: Research Increases Understanding of Lupus, RA

FOCIS 2015: Research Increases Understanding of Lupus, RA

October 13, 2015 • By Catherine Kolonko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Not all neutrophils are created equal, and they also have more than one route to cell death, Dr. Kaplan said. Enter NETs, an interconnected group of extracellular neutrophil fibers that bind themselves to pathogens and release DNA that promotes inflammatory responses in lupus.

You Might Also Like
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
  • Rheumatology Research Foundation to Play Role in Developing New RA, Lupus Treatments
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
Explore This Issue
October 2015

Research indicates that NETs are strong inducers of type 1 interferons, which amplify vascular damage and may play a role in the development of vascular‑related lesions seen in lupus, Dr. Kaplan said. Other studies indicate that NETs may be a strong activator to NLRP3 inflammasome machinery in macrophages, she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In concluding her talk, Dr. Kaplan proposed that aberrant neutrophils play prominent roles in lupus through the modification and externalization of antigens that amplify the body’s immune response.

Interferon in Lupus

Dr. Elkon

Dr. Elkon

The discussion of lupus continued with Keith Elkon, MD, head of the rheumatology division at University of Washington School of Medicine, Seattle. He began by noting that interferon is thought to be very important in lupus, and in many patients there is a striking signature of interferon in the skin.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Elkon reviewed ongoing research on skin-related disease flares in lupus that are triggered by sunlight, and he shared results from an unpublished study on mice exposed to ultraviolet (UV) light. The study took a systematic approach to expose normal mice to UVB light every day at around the same time for five consecutive days.

Rather than taking an animal and exposing it to a high dose of UV light and seeing what is stimulated, the researchers wanted to “make it more similar to what goes on for a human walking around in the sunlight,” Dr. Elkon explained. Skin changes, such as rashes and lesions, are an important part of lupus diagnosis criteria.

Researchers observed changes at each time point, conducted biopsies to analyze cell infiltrates and looked at reduced cytokines and activated pathways. Results showing a modest induction of type 1 interferon led them to further test interferon-receptor knock-out mice to see what would happen when interferon stimulation is blocked.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“To our surprise, instead of making this disease better, it actually made it worse,” Dr. Elkon said.

There was increased inflammation and increased redness in skin lesions. There was also an increase in inflammatory cytokines, TNF IL-6 and IL-1.

“So if you take away interferon, you actually get an increase in the inflammatory response,” Dr. Elkon said. “So that of course tells us that type 1 interferon in these animals may actually suppress inflammation.”

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis, SLE (Lupus) Tagged With: Lupus, patient care, RA, Research, Rheumatoid arthritis, SLE, Systemic lupus erythematosus, Treatment, trialIssue: October 2015

You Might Also Like:
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
  • Rheumatology Research Foundation to Play Role in Developing New RA, Lupus Treatments
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
  • Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.